Edit

Mirati Therapeutics

http://mirati.com/

Last activity: 11.11.2024

Active

Categories: BioTechDesignInformationLifeMediaMedTechScienceSocial

Our mission is to discover, design & deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. http://bit.ly/3lFIWB0

Followers

1.04K

Website visits

31.7K /mo.

Mentions

Location: United States, California, San Diego

Employees: 201-500

Founded date: 1995

Twitter

Facebook

Investors 2

Date	Name	Website
-	Avoro Capi...	avorocapit...
-	Internatio...	ibtplc.com

Mentions in press and media 23

Date	Title	Description
14.11.2024	Navigating the Future of Biopharma: Sobi's Meeting and TRexBio's Funding Surge	In the ever-evolving landscape of biopharmaceuticals, two significant events recently captured the industry's attention. Swedish Orphan Biovitrum AB (Sobi) announced an Extraordinary General Meeting, while TRexBio secured a hefty $84 millio...
11.11.2024	Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)	Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ) Mon, Nov 11, 2024 08:00 CET Report this content The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Ex...
10.11.2023	The first vaccine for the increasingly prevalent chikungunya virus is here	Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we have two FDA approvals, preview late-breakers at this weekend’s American Heart Association scientific sessi...
06.01.2023	Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	SAN DIEGO, Jan. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. MRTX, a clinical-stage targeted oncology company, today announced that the company granted equity awards to 6 new employees with a grant date of January 3, 2023, as equity in...
17.11.2021	Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers	SAN DIEGO, Nov. 17, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Adm...
11.11.2021	Mirati Therapeutics Announces Pricing of Public Offering of Common Stock	SAN DIEGO, Nov. 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, today announced the pricing of an underwritten public offering of 3,448,275 shares of its common stock at a price...
10.11.2021	Mirati Therapeutics Announces Proposed Public Offering of Common Stock	SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) a clinical-stage oncology company, today announced that it intends to offer and sell in an underwritten public offering $500 million of shares of its common st...
08.10.2021	Mirati teams with Sanofi on PhI/II trial for KRAS treatment combo; AbbVie loses in latest Humira biosimilar development	Charles Baum Mirati and Sanofi on Friday announced their new non-exclusive, clinical collaboration to evaluate combining Mirati’s investigational KRAS G12C inhibitor adagrasib with Sanofi’s investigational SHP2 ...
20.09.2021	Mirati Therapeutics : Announces Positive Phase 2 Topline Results for Investigational Adagrasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer	SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive topline results from the potentially registration-enabling cohort of the Phase 2 KRYSTA...
20.09.2021	Mirati Therapeutics : Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Che...	SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500. Results showed dura...
24.06.2021	Mirati Therapeutics' : Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation	SAN DIEGO, June 24, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ...
25.02.2021	Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate Updates
25.02.2021	Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate Updates	SAN DIEGO, Feb. 25, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today reported financial results for the fourth quarter and full year of 2020, which reflect the company's progress a...
13.02.2021	Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med	If you’re a big KRAS G12C fan, mark your calendars for October 28 at 4:20 pm EDT. That’s when Mirati $MRTX will unveil its first peek at the early clinical data available on MRTX849 in presentations at the AACR-NCI-EORTC International Confe...
17.09.2020	Boehringer Ingelheim And Mirati Therapeutics Announce Clinical Collaboration To Study BI 1701963, A SOS1::pan-KRAS Inhibitor In Combination With MRTX849, A KRAS G12C Selective Inhibitor
06.01.2020	Merck partners with Taiho, Otsuka in $2.5B bet on KRAS-targeting cancer drugs	Financial terms of the deal include a $50 million upfront payment for Taiho and Astex, as well as up to $2.5 billion in milestones. Merck operates under the name MSD outside the U.S. and Canada to avoid confusion with Germany-based Merck KG...
29.10.2019	Mirati presents data on drug with tough-to-reach target, setting up competition with Amgen	Shares of Mirati rose 16.5 percent on the Nasdaq Tuesday morning following the news. Amgen is developing the drug AMG 510, which is also a KRAS G12C inhibitor that has shown encouraging early data. “Patients whose tumors carry the KRAS G12C...
26.04.2019	Celebrating sustained sales growth, AstraZeneca quietly executes some aging mid-stage drug projects	While AstraZeneca execs clustered by the front door to discuss their third straight quarter with rising sales driven by new cancer drugs and an expanding grasp of the Chinese market, the company’s R&D janitors were sweep...
22.10.2018	Beyond the headline: Mirati undersells concerning data on its lung cancer immunotherapy	Is the clinical and regulatory update Mirati Therapeutics (MRTX) provided Monday for its lead lung cancer cancer immunotherapy drug really positive? That’s what the biotech chose to say in the headline of its press release. The details, dis...
-	Mirati presents data on drug with tough-to-reach target, setting up competition with Amgen	Amgen’s drug for an “undruggable” cancer target had its first data out earlier this year, but its already got some potential competition. San Diego-based Mirati Therapeutics announced Monday the presentation of data from the Phase I/II stud...
-	Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021	SAN DIEGO, March 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced it will present initial preclinical data on the Company's synthetic lethal PRMT5 inhibitor during a ...
-	Built for the challenge of KRASG12C: A new treatment option for 2L KRASG12C-mutated NSCLC	Non-small cell lung cancer (NSCLC) patients and providers now have a new treatment option following the U.S. Food and Drug Administration’s approval of KRAZATI® (adagrasib), Mirati Therapeutics’ KRASG12C inhibitor for the treatment of adult...
-	Merck partners with Taiho, Otsuka in $2.5B bet on KRAS-targeting cancer drugs	A Japanese drugmaker is teaming up with subsidiaries of one of the largest pharmaceutical companies in the U.S. and another Japan-based company to develop small-molecule oncology drugs, including those targeting a hard-to-reach gene express...

Mirati Therapeutics

Investors 2

Mentions in press and media 23

Reviews 0